Effect of Rifaximin on Abdominal Bloating in SIBO Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the efficacy of rifaximin, an antibiotic, in treating patients with Small Intestinal Bacterial Overgrowth (SIBO) who experience abdominal bloating. Participants will undergo breath testing to diagnose SIBO and will be treated with rifaximin for two weeks while documenting their symptoms and any adverse reactions. Follow-up assessments will include repeat breath tests and symptom evaluations at one, three, and six months post-treatment. The study aims to better understand the relationship between SIBO and bloating symptoms and the effectiveness of rifaximin in alleviating these symptoms.

Why it matters

Who can join: the full rules

Healthy Group

Inclusion Criteria:

1. Age between 18 and 70 years, both genders included.
2. No special gastrointestinal discomfort such as bloating or abdominal pain, regular bowel movements, and normal stool characteristics.
3. Negative hydrogen/methane breath test.

Exclusion Criteria:

1. Pregnant or lactating women.
2. History of gastrointestinal malignancy or gastrointestinal surgery.
3. Past diagnosis or suspicion of lactose intolerance.
4. Confirmed extra-digestive system diseases such as urinary system (chronic kidney disease, etc.), immune system (scleroderma, etc.), nervous system (Parkinson's, etc.), endocrine system (diabetes, etc.).
5. Abnormalities in professional anxiety and depression symptom rating scales.
6. Use of antibiotics, probiotics within two weeks, endoscopic examination, or use of prokinetics, secretagogues, antifoaming agents, antispasmodics, opioids, antidepressants within one week.
7. Those who cannot or are unwilling to sign an informed consent form.

Patient Group:

Inclusion Criteria:

1. Age between 18 and 70 years, both genders included.
2. Chief complaints of abdominal bloating and/or distension; outpatients with abdominal bloating and/or distension more prominent than other symptoms.
3. Positive hydrogen/methane breath test.

Exclusion Criteria:

1. Pregnant or lactating women.
2. History of gastrointestinal malignancy or gastrointestinal surgery.
3. Past diagnosis or suspicion of lactose intolerance.
4. Confirmed extra-digestive system diseases such as urinary system (chronic kidney disease, etc.), immune system (scleroderma, etc.), nervous system (Parkinson's, etc.), endocrine system (diabetes, etc.).
5. Moderate to severe abnormalities in professional anxiety and depression symptom rating scales.
6. Use of antibiotics, probiotics within two weeks, endoscopic examination, or use of prokinetics, secretagogues, antifoaming agents, antispasmodics, opioids, antidepressants within one week.
7. Those who cannot or are unwilling to sign an informed consent form.

Where it's running

• Qilu Hospital of Shandong University
  Jinan, Shandong, China Recruiting

Study contacts

• Study coordinator: Xiuli Zuo, MD,PhD
• Email: zuoxiuli@sdu.edu.cn
• Phone: 15588818685

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding links between severe periodontitis and gut bacteria and barrier function

  This observational study tests whether severe periodontitis is related to small intestinal bacterial overgrowth (SIBO) and changes in gut barrier biomarkers in adults.

  Recruiting Iuliu Hatieganu University of Medicine and Pharmacy · Cluj-Napoca · NCT07907224

• Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

  This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

  Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

• Testing a new catheter for better fluid collection during endoscopy

  This study is testing a new type of catheter to see if it can collect fluid from the small intestine more effectively during endoscopy for patients undergoing the procedure.

  Recruiting Cedars-Sinai Medical Center · Los Angeles, California · NCT04418258

• Artemisia annua for hydrogen-type small intestinal bacterial overgrowth (SIBO)

  This trial will try 5 grams a day of dried Artemisia annua leaves or a placebo in adults with hydrogen-type SIBO to see if it is safe and helps symptoms.

  Recruiting Phase 1/2 National University of Natural Medicine · Portland, Oregon · NCT06721884

• Using urine samples to diagnose gastrointestinal diseases

  This study is testing a new way to use urine samples to see if it can help diagnose different gastrointestinal diseases like colorectal cancer and Crohn's disease.

  Recruiting at 4 sites Luventix, Inc. · Encinitas, California and 3 other locations · NCT06710067

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.